目的:我们的目标是探索不同治疗方法的潜力,包括perhexiline,钙通道阻滞剂,抗高血压药,PDE5抑制剂,抗心绞痛药物,醛糖还原酶抑制剂,和SGLT-2抑制剂,有临床证据支持。此外,本综述旨在确定改善糖尿病人群心血管结局的新治疗靶点和未来途径.
方法:我们对跨多个电子数据库的英语研究进行了全面的文献综述,比如PubMed,ScienceDirect,Scopus,和谷歌学者,专注于临床试验。搜索使用的关键字包括\'抗高血糖药物,\'\'糖尿病心肌病,\'\'DPP-4抑制剂,GLP-1受体激动剂,\'\'心力衰竭,\'和\'SGLT-2抑制剂。
结果:我们评估了心肌病和糖尿病(DM)治疗的临床研究,这些研究通过评估Polypill的试验增强了我们的理解,Perhexiline,Eplerenone,IMB-1018972,AT-001,他达拉非,和达格列净抑制剂.由于忽视了早期症状,开发新的针对性干预措施至关重要。所涉及的细胞和分子途径的复杂性,以及缺乏有效的药物治疗。
结论:药物治疗,如GLP-1激动剂,SGLT-2抑制剂,NHE-1、NHE-3和PPAR-γ激动剂显示出治疗DCM的希望。这些治疗改善心肌葡萄糖吸收,解决葡萄糖和脂质代谢失调,和降低心力衰竭和心血管事件。需要进一步的研究来确认有效性和安全性。
OBJECTIVE: We aim to explore the potential of diverse treatments, including perhexiline, calcium channel blockers, anti-hypertensives, PDE5 inhibitors, anti-anginal drugs, aldose reductase inhibitors, and SGLT-2 inhibitors, supported by clinical evidence. Additionally, this review seeks to identify novel therapeutic targets and future avenues for improving cardiovascular outcomes in diabetic populations.
METHODS: We performed a comprehensive literature review of English-language studies across multiple electronic databases, such as PubMed, ScienceDirect, Scopus, and Google Scholar, focusing on clinical trials. The search utilized keywords including \'Anti-hyperglycaemic drug,\' \'Diabetic cardiomyopathy,\' \'DPP-4 inhibitors,\' \'GLP-1 receptor agonists,\' \'Heart failure,\' and \'SGLT-2 inhibitors.\'
RESULTS: We assessed clinical investigations in the treatment of cardiomyopathy and diabetes mellitus (DM) that are enhancing our understanding through trials evaluating the Polypill, Perhexiline, Eplerenone, IMB-1018972, AT-001, tadalafil, and dapagliflozin inhibitors. The development of new targeted interventions is of paramount importance due to the overlooked early symptoms, the complexity of the cellular and molecular pathways involved, and the absence of effective drug therapies.
CONCLUSIONS: Pharmacological treatments like GLP-1 agonists, SGLT-2 inhibitors, NHE-1, NHE-3, and PPAR-γ agonists show promise for treating DCM. These treatments improve myocardial glucose absorption, address dysregulated glucose and lipid metabolism, and lower heart failure and cardiovascular events. Further research is needed to confirm effectiveness and safety.